BRC earns US marketing approval
Friday, 28 October, 2005
The Brain Resource Company (ASX:BRC) has been granted approval from the US FDA to market its methodology and standardised international human brain database.
The company already has approval to market to pharmaceutical companies for clinical trials and this now extends access to qualified medical practitioners.
"This represents a substantial increase in our addressable market, with significant implications for our growth potential," said BRC's chairman and CEO, Evian Gordon. "Our method uses electrical measures of the brain to look at speed of information processing and secondly provides information from real world tests that monitor such things as memory, attention and planning.
"This is the world's first standardised international database on the human brain -- it holds details of over 4000 individuals, and is currently accessed by 60 groups in the US, Europe, South Africa and Australia," he said.
BRC currently has deals with 14 pharmaceutical companies for their brain methodology including Bristol-Myers Squibb, Johnson & Johnson, GlaxoSmithKline, Bayer, Eli Lilly, Pfizer and Biogen.
mRNA successfully delivered through blood–brain barrier
Getting mRNA into the brain could allow scientists to instruct brain cells to produce therapeutic...
Biological computer could revolutionise medical sciences
The CL1 is a commercial biological computer which fuses lab-cultivated neurons from human stem...
Genetic risk of schizophrenia impacts men and women differently
Men tend to present different clinical symptoms from women, poorer premorbid functioning and...
